Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Capricor, seeking lifeline for Duchenne therapy, says it will ask FDA to review additional data

14 August 2026 · By · Wire by Fusion42

Published

14 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at endpoints.news →

◆ Verified

Fusion42 · 14 August 2026 · Fusion42 review

Capricor Therapeutics plans to request the FDA to review additional data for its Duchenne muscular dystrophy therapy as part of efforts to secure approval for its clinical treatment.

This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it between 14 Aug 2026 and 25 Aug 2026.

◆ ◆ The Wire takeaway

FDA review windows can reopen with new data submissions, giving you a chance to extend regulatory timelines and revive stalled approvals. If you work in gene therapy or rare disease drug development, prepare for last-minute review opportunities that could change your go-to-market timing.

◆ Coverage

7 sources · first reported 14 Aug 2026 · latest 25 Aug 2026

◆ Related on Wire

◆ Topics

Biotechfdadrug-approvalduchenne-therapyclinical-trialsbiotech